Advaxis Asset Sale Approved by Majority Shareholder Vote
Company Announcements

Advaxis Asset Sale Approved by Majority Shareholder Vote

Advaxis (ADXS) has released an update to notify the public and investors about the submission of matters to a vote of security holders.

On February 5, 2024, a company entered into an agreement with Immunome, Inc. to sell the majority of its assets, specifically its AL101 and AL102 programs. This significant move was approved by the company’s board and received the necessary stockholder consent, with over 78% of voting power backing the sale. The company plans to inform the SEC and its stockholders about the details of this asset purchase agreement and the related transactions through an upcoming information statement.

For further insights into ADXS corporate activity, check out TipRanks’ Insiders Trading Activity page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TipRanks Auto-Generated NewsdeskAdvaxis Executive Reshuffle Following Asset Sale
TheFlyImmunome price target raised to $33 from $27 at Wedbush
TipRanks Auto-Generated NewsdeskAdvaxis Enhances Operations Through Strategic Asset Sale
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App